GLP-1 Pros and Cons

Summary: GLP-1 receptor agonists work well for the people they work for, but they come with real tradeoffs that not every patient should accept.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

GLP-1 receptor agonists work well for the people they work for, and they come with real tradeoffs that not every patient should accept. The honest version of the pros and cons looks like this: the upside numbers from the trials are larger than almost any other class of drug delivers, and the downsides are larger than the marketing wants you to think about. Whether the math comes out positive for you depends on your weight, your cardiometabolic risk, your insurance, and how you feel about taking a drug you may need to stay on indefinitely.

This page is the long-form balance sheet. Pros first, cons second, then a short section on who should consider these drugs and who should think harder before starting.

The pros, with the actual numbers

Weight loss that nothing else in the pharmacy delivers

Semaglutide 2.4 mg weekly produced a mean weight loss of 14.9% of body weight at 68 weeks in STEP-1, versus 2.4% for placebo. About 86% of patients on the active drug lost at least 5% of body weight, and 32% lost at least 20% ^[1]. Those are placebo-adjusted, randomized-trial numbers in adults with overweight or obesity without diabetes.

Tirzepatide raised the bar again. In SURMOUNT-1, the 15 mg weekly dose produced a mean weight loss of 20.9% at 72 weeks, with 57% of participants losing at least 20% of body weight and 36% losing at least 25% ^[2]. No prior pharmacologic class came close to those numbers. Bariatric surgery still beats them at the high end, but tirzepatide narrows the gap considerably.

For context, older weight-loss drugs (orlistat, phentermine/topiramate, naltrexone/bupropion) generally produce 5 to 9% placebo-adjusted weight loss. GLP-1s roughly doubled that. Tirzepatide roughly tripled it.

A1C improvement for type 2 diabetes

GLP-1s and the GIP/GLP-1 dual agonist tirzepatide are now first-line or near-first-line additions to metformin for type 2 diabetes in most guidelines. Semaglutide drops A1C by roughly 1.5 to 1.8 percentage points at therapeutic doses. Tirzepatide drops it by roughly 2.0 to 2.5 points at the 10 and 15 mg doses. The effect happens with low hypoglycemia risk when used as monotherapy or with metformin, because GLP-1 insulin secretion is glucose-dependent.

Cardiovascular benefit in high-risk patients

This is the underrated pro. In the SELECT trial, semaglutide 2.4 mg weekly reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 20% in adults with established cardiovascular disease and overweight or obesity, without diabetes ^[3]. That is a primary-endpoint MACE reduction in a population where the only previously proven strategy at that scale was statins.

The kidney signal is similar. Pooled trial data show GLP-1 and dual agonist therapy slows progression of diabetic kidney disease. The FLOW trial in 2024 confirmed semaglutide reduced major kidney events in adults with type 2 diabetes and CKD.

Once-weekly dosing and good real-world adherence

Most modern GLP-1s dose once weekly subcutaneously. That is far easier to sustain than the daily injections of older versions (exenatide BID, lixisenatide, liraglutide). Weekly oral semaglutide exists in tablet form (Rybelsus), but absorption is finicky and the dose-equivalence to injectable is lower. For most patients, weekly injection wins on adherence.

Tolerated by most, in the long run

The headline side effect rates look intimidating until you read the discontinuation rates. In STEP-1, treatment discontinuation due to adverse events was 4.5% on semaglutide versus 0.8% on placebo ^[1]. In SURMOUNT-1 on tirzepatide it was 6.2% at the 15 mg dose ^[2]. Most patients who titrate slowly and stick with the protocol tolerate the drugs long enough to reach maintenance. The GI side effects are real, and for most people they fade.

The cons, with equal honesty

GI side effects are the price of admission

Nausea, vomiting, diarrhea, constipation, abdominal pain, and reflux are the most common side effects across the class. In STEP-1, 74% of semaglutide-treated patients reported any GI event versus 48% on placebo ^[1]. Nausea alone hit 44% on active drug. In SURMOUNT-1, GI events on tirzepatide 15 mg ran 47% for nausea, 23% for diarrhea, 24% for vomiting, and 17% for constipation ^[2].

These rates drop with slow titration and they usually fade after the first few weeks at each dose step. They do not always fade. A meaningful minority of patients hits a tolerance ceiling where every dose escalation brings back the nausea, and they end up stuck at a sub-therapeutic dose or quit.

Cost. The big one.

Retail cash price for Wegovy or Zepbound runs $1,000 to $1,350 per month in the United States as of 2026. Without insurance coverage, a year on a brand GLP-1 is a $12,000+ expense. Insurance coverage for obesity (as opposed to type 2 diabetes) remains inconsistent. Medicare did not cover anti-obesity medication for most of the modern era; the 2024 CMS reinterpretation expanded coverage for cardiovascular indications (Wegovy for MACE reduction in patients with established CVD), but blanket obesity coverage is still patchy.

Compounded versions exist and run cheaper, but the FDA removed tirzepatide from the shortage list in late 2024 and semaglutide in early 2025, which legally restricted most large-scale compounding. The compounded market continues in narrower forms.

Rebound weight gain when you stop

This is the con most marketing pages bury. The STEP-4 trial answered the maintenance question directly. Participants on semaglutide 2.4 mg for 20 weeks were randomized to continue or switch to placebo for another 48 weeks. The continuation group kept losing weight (an additional 7.9%). The placebo-switched group regained 6.9% of body weight on average over those 48 weeks ^[4]. Across multiple follow-up analyses, roughly two-thirds of the weight lost on semaglutide returns within a year of stopping.

The clinical translation: for most patients, GLP-1 therapy is not a 6-month event. It is an indefinite medication for a chronic biological condition. Stopping returns most of the weight. That is not a failure of the drug; that is what every honest obesity researcher has been saying for decades about the biology of weight regain. But it changes the cost-benefit math if you were hoping for a finite course.

Thyroid C-cell tumor warning

Every GLP-1 receptor agonist label carries a boxed warning for thyroid C-cell tumors based on rodent studies. The drugs are contraindicated in personal or family history of medullary thyroid carcinoma (MTC) and in multiple endocrine neoplasia syndrome type 2 (MEN 2) ^[5]. The human epidemiology is reassuring; large observational studies have not confirmed a clinically meaningful MTC signal in humans. But the contraindication stands, and the boxed warning exists for a reason.

Pancreatitis risk

Acute pancreatitis is listed as a warning on every GLP-1 label. Trial event rates are low (0.1 to 0.2% per year, similar to or slightly above placebo in pooled data), but the symptom presentation (severe persistent abdominal pain, often radiating to the back, with vomiting) is one of the documented red flags for stopping the drug and getting evaluated.

Injection, for most formulations

Most GLP-1s are subcutaneous. Some patients hate needles. Oral semaglutide exists, but at lower potency for weight loss and with strict fasting and water-volume rules at dosing time. For most patients, the answer is a weekly injection. The needle is small and most users tolerate it within a few doses; for some, the needle is a non-starter.

Muscle loss inside the weight loss

A consistent finding in body composition substudies: about 25 to 40% of the weight lost on GLP-1 monotherapy comes from lean mass rather than fat mass. The percentages are similar to what happens during any large caloric deficit, but the absolute amount of muscle lost is meaningful when the total weight loss is 20% of body weight. The mitigation is straightforward and the trials did not require it: adequate protein intake (typically 1.4 to 1.8 g/kg of goal body weight daily) and consistent resistance training. People who do neither, lose more lean mass.

"Ozempic face" and cosmetic concerns

Rapid weight loss of any cause produces facial volume loss, which reads visually as gauntness, hollow cheeks, and accelerated skin aging. Branded as "Ozempic face" by the cosmetic industry, it is not specific to GLP-1s; it is what happens when adipose tissue retreats from the face during any large weight loss. Slower titration and slower weight loss reduce the cosmetic effect. So does maintenance of facial expression musculature.

Ethical and societal issues

Off-label aesthetic use by people who are not clinically overweight has driven much of the demand. That demand contributed to the 2022 to 2024 tirzepatide and semaglutide shortages that left diabetic patients rationing or switching off therapy. It is not the drugs' fault, but it is part of the honest pros-and-cons conversation. There is also the broader question of medicalizing a population-scale problem rooted in food environment and lifestyle, which has no clean answer.

The non-weight side effects worth knowing

Beyond the headline pros and cons, a longer list of secondary effects shows up in real-world reporting. Most are nuisance-level and pass.

None of those secondary effects override the headline pros for most patients, but they are real, and patients who feel any of them deserve to know they were not imagined.

Who should consider GLP-1 therapy

The strongest case applies when several of the following are true:

• BMI of 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, NAFLD).
• Established cardiovascular disease plus overweight or obesity. The SELECT data make semaglutide a reasonable cardioprotective addition independent of diabetes status ^[3].
• Type 2 diabetes that is not at A1C goal on metformin, especially with overweight or obesity.
• A history of repeated lifestyle-only weight loss attempts followed by regain, with metabolic markers worsening.
• Insurance coverage or the financial capacity to sustain the medication for at least a year, since stopping early returns most of the weight ^[4].

Who should think harder before starting

• Personal or family history of medullary thyroid carcinoma or MEN 2. This is a hard contraindication ^[5].
• Prior episode of acute pancreatitis, or pancreatic structural risk factors. Discuss carefully with your prescriber.
• Severe gastroparesis or other significant gastric motility disease.
• Pregnancy or planning pregnancy within the dosing window. Labels recommend stopping at least 2 months before conception.
• Patients seeking small cosmetic weight loss (5 to 10 pounds) without a clinical indication. The risk-benefit math does not work, and the supply impact on patients with real clinical need is real.
• Patients who cannot commit financially or logistically to long-term therapy. Stopping returns most of the lost weight, often with metabolic markers regressing toward baseline.
• Patients with significant eating disorder history, particularly binge eating disorder with bulimic features. GLP-1s have been studied in binge eating with promising results, but anorexia-spectrum disorders are a different conversation.

Pros and cons at a glance

Frequently asked questions about GLP-1 pros and cons

What is the single biggest pro of GLP-1 medications?

Magnitude of weight loss. Semaglutide produces about 15% mean weight loss and tirzepatide produces about 21%, both in placebo-controlled trials, which is unmatched by any other drug class.

What is the single biggest con?

The combination of cost and the fact that weight returns when you stop. Together they make GLP-1 therapy a likely indefinite expense, not a short course.

Do GLP-1 medications reduce heart attack and stroke risk?

Yes in high-risk patients. SELECT showed semaglutide reduced major cardiovascular events by 20% in adults with established cardiovascular disease and overweight or obesity, without diabetes.

How much weight comes back if I stop?

About two-thirds of the weight lost returns within a year of stopping, based on STEP-4 and follow-up analyses. The biology of regain is well documented across the obesity literature.

How common is nausea on GLP-1s?

Common. Roughly 44 to 47% of patients report nausea at therapeutic doses in the trials. For most, it fades within a few weeks of each dose step. Slow titration reduces it.

Are GLP-1 medications safe long-term?

Cumulative data out to 4 to 5 years are reassuring on cardiovascular, kidney, and overall safety. Boxed warnings for thyroid C-cell tumors and pancreatitis warnings remain. True very long-term (10+ year) data are still accumulating.

Does insurance cover GLP-1s for weight loss?

Inconsistently. Coverage is generally easier when prescribed for type 2 diabetes. Coverage for obesity alone varies by plan. Medicare expanded coverage for cardiovascular indications in 2024 but blanket obesity coverage is still limited.

Do GLP-1s cause muscle loss?

They cause weight loss, and roughly 25 to 40% of the lost weight is lean mass when no resistance training or high-protein intake is in place. Adequate protein (1.4 to 1.8 g/kg goal weight) and resistance training markedly reduce muscle loss.

What is Ozempic face?

A marketing term for facial volume loss that accompanies rapid weight loss of any cause. It is not specific to GLP-1s; any large weight loss reduces facial fat. Slower titration and weight loss reduce the cosmetic effect.

Who should not take GLP-1 medications?

Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, anyone with prior pancreatitis (use caution), and anyone planning pregnancy in the near term. Patients with severe gastroparesis also should not start.

Are GLP-1s a quick fix?

No. They are a chronic medication for a chronic biological condition. They produce large effects while taken and most effect is lost when stopped. They work best alongside protein-focused nutrition and resistance training.

Can I switch between semaglutide and tirzepatide?

Yes, under prescriber guidance. Switching is common, particularly for tolerability or coverage reasons. There is no formal washout requirement, but the new drug is started at its own initiation dose.

How to weigh the decision

The pros and cons list above is the inventory. The decision is yours, with your prescriber. The version that produces regret most often is starting without budgeting for long-term cost, without committing to the protein and training that protect lean mass, and without understanding that stopping returns most of the weight. The version that produces the best outcomes is the opposite: a clinical indication, an honest budget, a nutrition and training plan, and a willingness to stay on the drug as long as it is working.

The trial data is the most positive it has ever been for any anti-obesity or anti-diabetic therapy. The tradeoffs are real and they are not deal-breakers for most patients who fit the indication. Match yourself to the inventory, talk to a prescriber who has actually managed dozens of patients through titration, and make the call from a place of information rather than marketing.